Compare HSLV & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HSLV | ARDX |
|---|---|---|
| Founded | N/A | 2007 |
| Country | Canada | United States |
| Employees | 51 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | N/A | 2014 |
| Metric | HSLV | ARDX |
|---|---|---|
| Price | $4.94 | $5.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $15.14 |
| AVG Volume (30 Days) | 491.8K | ★ 4.7M |
| Earning Date | 05-28-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,607,000.00 |
| Revenue This Year | N/A | $37.75 |
| Revenue Next Year | $37.60 | $34.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.08 | $4.08 |
| 52 Week High | $6.77 | $8.40 |
| Indicator | HSLV | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 51.29 | 35.38 |
| Support Level | $4.10 | $4.87 |
| Resistance Level | $5.30 | $5.34 |
| Average True Range (ATR) | 0.27 | 0.32 |
| MACD | 0.06 | -0.07 |
| Stochastic Oscillator | 72.13 | 16.61 |
Highlander Silver Corp. is a mineral exploration company engaged in the acquisition, exploration and evaluation of mineral properties located in Peru. It is focused on advancing the bonanza grade San Luis gold-silver project that is located in Central Peru. The company has determined that it has one operating segment, being the exploration of mineral properties.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.